HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (NCT06594445)
HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory/relapsed myeloid malignancies in adults ≥ 18 years of age who are not a candidate for potentially curative therapy, including hematopoietic stem cell transplantation, and are refractory to, intolerant of, or ineligible for therapy options that are known to provide clinical benefit. The hypothesis is GTB-3650 TriKE will induce natural killer (NK) cell function by targeting malignant cells, as well as, CD33+ myeloid derived suppressor cells (MDSC) which contribute to a tumor induced immunosuppression. Because CD16 is the most potent activating receptor on NK cells, this single agent may induce a targeted antiCD33+ tumor response
Who can join: Review the eligibility criteria below.
Location: Masonic Cancer Center — Minneapolis, Minnesota
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Masonic Cancer Center — Minneapolis, Minnesota
📞 Contact the Study Coordinator
Phone: (612) 624-9452
Email: juck0001@umn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myeloid Malignancy
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms — Boston, Massachusetts
- Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories — Rochester, New York
- Pre-myeloid Cancer and Bone Marrow Failure Clinic Study — Scottsdale, Arizona
- Germline Testing for Predisposition to Myeloid Malignancies — Boston, Massachusetts
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies — Birmingham, Alabama
- A Telehealth Advance Care Planning Intervention — Rochester, New York
Explore by condition: All Myeloid Malignancy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.